Inactive

DESCRIPTION: The National Institutes of Health – NICHD- Section of Membrane Biology intends to procure the services of a contractor to provide nanobodies and Protein Expression. Scope: The Lab studies... DESCRIPTION: The National Institutes of Health – NICHD- Section of Membrane Biology intends to procure the services of a contractor to provide nanobodies and Protein Expression. Scope: The Lab studies mechanisms of cell-cell fusion underlying formation of different multinucleated cells playing important roles in different tissues. In their recent work, the lab has focused on cell-fusion in development of myofibers in our skeletal muscles; placental syncytiotrophoblast and bone resorbing osteoclasts. Each of these cell-fusion processes has very important biomedical applications and is linked to human diseases. Defects in trophoblast fusion result in placental diseases. A host of bone diseases afflict the wellbeing of millions of individuals in the United States each year that all have one common source, osteoclast dysfunction. The list of important diseases linked to insufficient or excessive formation of osteoclasts includes osteoporosis, Paget’s disease of bone, fibrous dysplasia, osteolytic bone metastasis, and others. Unfortunately, current therapeutics targeting these remodelers of the skeletal system exhibit numerous shortcomings. In a recent and still on-going work, the Lab has identified a novel biological target on the surface of osteoclasts that can be manipulated to specifically tune the function of osteoclasts in order to correct bone pathology in patients. They have identified methods for inhibiting the ability of these cells to remodel bone, which can be particularly useful for treating the many diseases where osteoclasts are overactive in individuals, including osteoporosis, Paget’s disease of bone, fibrous dysplasia, osteolytic bone metastasis, and others. They have discovered that SSB/Lupus La protein is vital for the cell fusion stage of osteoclastogenesis. Defects in myoblast fusion, including mutation in myomerger, one of the proteins involved in this fusion process result in muscle diseases. The studies on all these fusion processes depend on developing reagents reliably identifying these proteins. Nanobody (or monobody) is a small single domain, recombinantly produced target protein- binding reagent. Advantageous features of nanobodies include their small size, high solubility, high stability, and excellent tissue penetration in vivo. Nanobodies can readily be linked genetically to Fc-domains, other nanobodies, peptide tags, or toxins. For this project, the Lab needs nanobodies to three proteins: two of them are based on the sequence of La protein and one is based on the sequence of myomerger. The Lab will expect a full Web report and access to all sequences analyzed within a few weeks part of the Deliverables. Combined Synopsis/solicitation: Initial market research conducted by the Lab has shown availability of different models in Commercial market. The Lab has already solicited from different vendors, including the Center for Molecular Medecine- Protein Core, and received competitive quotes. This RFQ will award to the LPTA with all salient characteristics and compatibility with existing equipment at the Lab. The Lab/customer will provide 2.5mg Antigen and the Protein will be expressed and purified from the supplied plasmid. All quotes will be evaluated equally after close of this solicitation and award will be made thereafter.. The proposed contract action is for which the Government does not intend to solicit and negotiate with only one source under the authority of FAR 6.302. Instead, interested parties may identify their interest and capability to respond to the requirement and submit quotations. This notice is a request for competitive quotes and all quotes received within the time and date of publication of this Notice# HHSNNanobodies060821 will be considered by the Government. A determination by the Government not to compete with this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered for the purpose of determining whether to conduct a future competitive procurement. HOW TO RESPOND: In order to compete for this project, interested parties must be registered in the Central Contracting Registration/SAM and submit a price quotation by 10:00 am, ET, June 24th, 2021. Offerors should submit one copy of the quote to MOE FILALI via email. Electronic transmissions to Moe.Filali@nih.gov are preferable but must be timely. It is the responsibility of the Offeror to ensure the proposal is received by the date and time shown above. This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation and a separate written solicitation will not be issued. This solicitation number is HHSNNanobodies060821 and is issued as a Request for Quotation (RFQ). The solicitation/contract will include all applicable provisions and clauses in effect through Federal Acquisition Circular 2019-05. The offeror must include a completed copy of the provision of FAR Clause 52.212-3, Offeror Representations and Certifications – Commercial Items with its offer. The provisions of FAR Clause 52.212-1 Instructions to Offerors – Commercial Items; FAR Clause 52.212-2, Evaluation – Commercial Items; FAR Clause 52.212-4, Contract Terms and Conditions – Commercial Items; and FAR 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders – Commercial Items – Deviation for Simplified Acquisitions applies to this acquisition. FAR Clause 52.204-24, Representation Regarding Certain Telecommunication and Video Surveillance Services or Equipment; FAR Clause 52.204-25, Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment; FAR Clause 52.213-4 to reflect the changes in FAC 2019-05 and FAR Clause 52.244-6 to reflect the changes in FAC 2019-05. The offeror must include their Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. The clauses are available in full text at http://www.arnet.gov/far. Interested vendors capable of providing the Government with the equipment specified in this synopsis should submit their quotation to the below address. The quotation must reference “Solicitation number” HHSNNanobodies060821. All responsible sources may submit a quotation, which if timely received, shall be considered by the agency. Quotations must be submitted by email to Moe.filali@nih.gov. Faxed copies will not be accepted PLEASE NOTE: In order to receive an award, contractor must be registered and have valid certification in System for Award Management (SAM). The following Federal Acquisition Regulations clauses are incorporated by reference: FAR 52.212-3, Offeror Representations and Certifications-Commercial Items (Mar 2005), 52.212-4 (Sept 2005), 52.212-5, Contract Terms and Conditions Required to Implement Statutes of Executive Orders-Commercial Items (Aug 2006). (6)(i) 52.222-26, Equal Opportunity (Apr 2002) (E.O. 11246). (18) 52.222-35, Equal Opportunity for Special Disabled Veterans, Veterans of the Vietnam Era, and Other Eligible Veterans (Dec 2001) (38 U.S.C. 4212). (19) 52.222-36, Affirmative Action for Workers with Disabilities (Jun 1998) (29 U.S.C. 793). (20) 52.222-37, Employment Reports on Special Disabled Veterans, Veterans of the Vietnam Era, and Other Eligible Veterans (Dec 2001) (38 U.S.C. 4212). (31) 52.232-33, Payment by Electronic Funds Transfer-Central Contractor Registration (Oct 2003) (31 U.S.C. 3332). Primary Point of Contact: MOE FILALI Contracting Office Address: NIH/NICHD Office of Acquisitions 6710B Rockledge Drive, Room 1145D Bethesda, MD 20817 (w) 301.827 7737 Moe.filali@nih.gov